Racquel Bracken

Racquel holds a bachelor's degree in molecular and cellular biology from Harvard University, and conducted research on embryonic stem cells as a model for Parkinson's Disease at Harvard. 

​

Racquel also serves on the Young Leaders Council of the Livestrong Foundation.

Racquel recently joined Venrock in their Palo Alto, California office, investing in biotech, diagnostics, and healthcare IT sectors. 

​

Previously, Racquel headed business development at Clovis Oncology, a company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the US, Europe, and additional international markets. She was involved in the in-licensing of CO-1686 from Avila Therapeutics (now Celgene), Rucaparib from Pfizer, and the discovery partnership with Array. 

​

Earlier, Racquel was on the investment team at Domain Associates, where her board observer positions include Acureon Pharmaceuticals, Asmacure, Immune Control, Nuon Therapeutics, OmniSonics, and VentiRx. Racquel also assisted Calixa Therapeutics, a biopharmacuetical company dedicated to the clinical development of anti-gram negative therapeutic agents, where she was responsible for business development activities. 

​

Before Domain Associates, Racquel was a consultant with Easton Associates (now Navigant Consulting), where she worked with clients ranging from startups to global pharmaceutical and device companies. She advised clients on general corporate strategy, marketing and sales tactics, product life-cycle planning, clinical development plans, M&A opportunities, and business development activities.

Racquel is a member of Class 13 and served her fellowship at Domain Associates and Clovis Oncology under the mentorship of Brian Halak.